# Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

> **NCT00522821** · PHASE4 · COMPLETED · sponsor: **Prothya Biosolutions** · enrollment: 55 (actual)

## Conditions studied

- IgG Deficiency
- Infections

## Interventions

- **DRUG:** intravenous immunoglobulins
- **DRUG:** antibiotics

## Key facts

- **NCT ID:** NCT00522821
- **Lead sponsor:** Prothya Biosolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522821, "Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00522821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*